Researcher.Life Logo

Hematology/ Oncology and Stem Cell Therapy : Impact Factor & More

eISSN: 2589-0646pISSN: 1658-3876
JournalOpen Access

Aims and Scope of Hematology/ Oncology and Stem Cell Therapy

Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value. Less

Key Metrics

CiteScore
3
SJR
Q3Oncology
SNIP
1
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Hematology/ Oncology and Stem Cell Therapy

Hematology/ Oncology and Stem Cell Therapy Journal Specifications

Indexed in the following public directories

  • Scopus Scopus
  • SJR SJR
Overview
Publisher Elsevier
Language English
Publication Time27
Editorial Review ProcessDouble blind peer review
General Details
LanguageEnglish
Society/Institute/SponsorKing Faisal Specialist Hospital & Research Centre
Website URLVisit website
Publication Details
Publication Time 27
Editorial Review Detail
Editorial TeamVisit website
Review ProcessDouble blind peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Hematology/ Oncology and Stem Cell Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Hematology/ Oncology and Stem Cell Therapy

Progressive transformation of germinal centers: Bridging clinical and pathological insights for diagnostic precision.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Cancer epidemiology in the Kingdom of Saudi Arabia, 2024.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action.
  • 1 Oct 2025
  • Hematology/oncology and stem cell therapy
Progressive transformation of germinal centers: Bridging clinical and pathological insights for diagnostic precision.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Cancer epidemiology in the Kingdom of Saudi Arabia, 2024.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
  • 1 Feb 2026
  • Hematology/oncology and stem cell therapy
Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action.
  • 1 Oct 2025
  • Hematology/oncology and stem cell therapy

FAQs on Hematology/ Oncology and Stem Cell Therapy